News | ECG | October 19, 2022

HeartSciences Announces Major Milestone with the Issuance of CPT Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction

Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences’ MyoVista

Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences’ MyoVista

October 19, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today reports that the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for novel AI assistive algorithmic ECG risk assessment for cardiac dysfunction. These codes are expected to cover the AI cardiac dysfunction algorithm incorporated in the Company’s MyoVista Wavelet ECG Cardiac Testing Device currently in development for FDA De Novo submission and clearance. The codes are in addition to the long-established CPT codes in place for the conventional ECG. 

CPT Category III codes are designed to facilitate the use, adoption, and potential reimbursement of emerging technologies. The new CPT codes go into effect in the CPT codebook on January 1, 2023. 

“This is a major milestone for HeartSciences. The issuance of new CPT codes by the AMA acknowledges the importance of AI analysis of cardiac dysfunction using an ECG. It also further validates the commercial opportunity for the MyoVista,” stated Andrew Simpson, Chief Executive Officer of HeartSciences. “One of the most significant needs in healthcare is the ability to detect cardiac dysfunction early. An AI-enabled ECG is a relatively low-cost, simple, and quick way to do that. Millions of ECG tests are performed every week and we believe adding detection of cardiac dysfunction to the ECG would make it a far more valuable heart screening tool.” 

For more information: https://www.heartsciences.com 


Related Content

News | Artificial Intelligence

November 23, 2022 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today ...

Home November 23, 2022
Home
News | Artificial Intelligence

November 21, 2022 — Artificial intelligence can improve diagnosis and treatment for patients, but first the AI-enabled ...

Home November 21, 2022
Home
News | Artificial Intelligence

November 16, 2022 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today ...

Home November 16, 2022
Home
News | Artificial Intelligence

November 16, 2022 — A study published in Nature Medicine reports the ability of a smartwatch ECG to accurately detect ...

Home November 16, 2022
Home
News | Artificial Intelligence

September 29, 2022 — Researchers at Mayo Clinic used artificial intelligence (AI) to evaluate patients’ ...

Home September 29, 2022
Home
News | Artificial Intelligence

September 22, 2022 — Medical imaging specialist Avicenna.AI announced a groundbreaking partnership with the MedTech ...

Home September 22, 2022
Home
News | Artificial Intelligence

September 2, 2022 — In patients undergoing echocardiographic evaluation of cardiac function, preliminary assessment by ...

Home September 02, 2022
Home
News | Artificial Intelligence

August 29, 2022 — In a first-of-its-kind randomized clinical trial led by researchers at the Smidt Heart Institute and ...

Home August 29, 2022
Home
News | Artificial Intelligence

August 18, 2022 — Six digital healthcare start-ups from five countries have officially become the first cohort of the ...

Home August 18, 2022
Home
News | Artificial Intelligence

August 16, 2022 — Dyad Medical, Inc., the developer of the cloud-based AI technology for cardiac image analysis ...

Home August 16, 2022
Home
Subscribe Now